YaoPharma’s once-daily oral GLP-1 drug is currently in Phase 1 testing. The license agreement gives Pfizer global rights to the small molecule, which it envisions as part of potential drug combinations.Fresh off the acquisition of metabolic medicines developer Metsera, Pfizer is again turning to dealmaking to expand its obesity drug pipeline, this time picking up […]
